文献速递系统性红斑狼疮其他结缔组织病

机器学习识别自身免疫性疾病中抗SSA/Ro 60抗体表达的共有特征

Machine Learning for the Identification of a Common Signature for Anti-SSA/Ro 60 Antibody Expression Across Autoimmune Diseases.
PubMed 文献 · Arthritis Rheumatol · 2022-08-25

本研究利用PRECISESADS研究横断面队列的高通量多组学数据,采用机器学习比较520例抗Ro 60阳性患者与511例抗Ro 60阴性患者及279例健康对照的整合分子谱。结果显示抗Ro 60阳性患者存在跨疾病类型的特异性炎症特征,富含干扰素刺激基因,且该特征随时间稳定、不受治疗影响。

要点

  • ATP10A、MX1和PARP14三个基因的转录Z评分在抗Ro 60阳性患者中明显高于抗Ro 60阴性患者,且不受疾病类型影响。
  • 这些特征富含干扰素刺激基因,在类风湿关节炎和系统性硬化症的抗Ro 60阳性患者中同样存在。
  • 特征随时间保持稳定且不受治疗影响,作者认为可考虑同时靶向Ro相关RNA和抗Ro 60自身抗体的双重治疗策略。

核心结论

  • 抗Ro 60阳性患者无论疾病类型均存在特异性炎症特征,作者认为应考虑同时靶向Ro相关RNA和抗Ro 60自身抗体的双重治疗策略。

研究设计与样本

  • 基于PRECISESADS研究创新药物计划项目横断面队列的高通量多组学数据(遗传、表观基因组和转录组数据,结合流式细胞术、多重细胞因子、经典血清学和临床数据),使用机器学习评估520例抗Ro 60阳性患者与511例抗Ro 60阴性患者及279例健康对照的整合分子谱。

主要发现

  • RNA-Seq、DNA甲基化和全基因组关联研究数据中选出的临床特征可清晰区分抗Ro 60阳性与抗Ro 60阴性患者。
  • 机器学习从抗Ro 60阳性患者中选出的不同特征与抗Ro 60阴性患者和健康对照相比构成特异性特征。
  • ATP10A、MX1和PARP14三个基因的转录Z评分在抗Ro 60阳性患者中明显高于抗Ro 60阴性患者,且与疾病类型无关,这些基因的过表达与低甲基化和遗传变异相关,并由Boruta算法独立识别。
  • 这些特征富含干扰素刺激基因,在类风湿关节炎和系统性硬化症的抗Ro 60阳性患者中同样存在,且随时间保持稳定、不受治疗影响。

关键数值与推荐

  • 研究纳入520例抗Ro 60阳性患者、511例抗Ro 60阴性患者(包括原发性干燥综合征、系统性红斑狼疮和未分化结缔组织病患者)及279例健康对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Anti-Ro autoantibodies are among the most frequently detected extractable nuclear antigen autoantibodies, mainly associated with primary Sjögren's syndrome (SS), systemic lupus erythematosus (SLE), and undifferentiated connective tissue disease (UCTD). This study was undertaken to determine if there is a common signature for all patients expressing anti-Ro 60 autoantibodies regardless of their disease phenotype. METHODS: Using high-throughput multiomics data collected from the cross-sectional cohort in the PRECISE Systemic Autoimmune Diseases (PRECISESADS) study Innovative Medicines Initiative (IMI) project (genetic, epigenomic, and transcriptomic data, combined with flow cytometry data, multiplexed cytokines, classic serology, and clinical data), we used machine learning to assess the integrated molecular profiling of 520 anti-Ro 60+ patients compared to 511 anti-Ro 60- patients with primary SS, patients with SLE, and patients with UCTD, and 279 healthy controls. RESULTS: The selected clinical features for RNA-Seq, DNA methylation, and genome-wide association study data allowed for a clear distinction between anti-Ro 60+ and anti-Ro 60- patients. The different features selected using machine learning from the anti-Ro 60+ patients constituted specific signatures when compared to anti-Ro 60- patients and healthy controls. Remarkably, the transcript Z score of 3 genes (ATP10A, MX1, and PARP14), presenting with overexpression associated with hypomethylation and genetic variation and independently identified using the Boruta algorithm, was clearly higher in anti-Ro 60+ patients compared to anti-Ro 60- patients regardless of disease type. Our findings demonstrated that these signatures, enriched in interferon-stimulated genes, were also found in anti-Ro 60+ patients with rheumatoid arthritis and those with systemic sclerosis and remained stable over time and were not affected by treatment. CONCLUSION: Anti-Ro 60+ patients present with a specific inflammatory signature regardless of their disease type, suggesting that a dual therapeutic approach targeting both Ro-associated RNAs and anti-Ro 60 autoantibodies should be considered.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Foulquier N, Le Dantec C, Bettacchioli E, et al. Machine Learning for the Identification of a Common Signature for Anti-SSA/Ro 60 Antibody Expression Across Autoimmune Diseases. Arthritis Rheumatol. 2022. PMID: 35635731. doi:10.1002/art.42243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。